Imatinib 800 mg Associated With Faster MMR vs Imatinib 400 mg or Imatinib 400 mg Plus Interferon in Previously Untreated Chronic-Phase CML. June 11, 2010- German CML Study IV: randomized, treatment optimization trial......
June 11, 2010- German CML Study IV: randomized, treatment optimization trial......
http://www.clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202010/
Tracks/Hematologic%20Malignancies/Capsules/6517.aspx
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year
Read more here: http://abstract.asco.org/AbstView_74_51091.html
Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM)
Abstract: read more here: http://abstract.asco.org/AbstView_74_52917.html
Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib.
Abstract: read more here: http://abstract.asco.org/AbstView_74_52814.html
Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib
Abstract: read more here: http://abstract.asco.org/AbstView_74_53560.html
Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.
Abstract: read more here: http://asco.org/AbstView_74_53232.html